Physician profile
Rohan Samson
NPI 1679705263
$93,651.05
in general payments reported to CMS, 2019-2025
40 companies · $80K in 2025
The $80K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $181 · 2021: $174 · 2022: $1,682 · 2023: $8,833 · 2024: $2,205 · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Travel and Lodging: $11K · Food and Beverage: $7,650 · Consulting Fee: $2,880 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,982.00 |
| Travel and Lodging | $10,738.52 |
| Food and Beverage | $7,649.96 |
| Consulting Fee | $2,880.00 |
| Education | $127.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $78,015.43 | 2022-2025 | Camzyos, Eliquis |
| Siemens Medical Solutions USA, INC. | $7,150.00 | 2023 | |
| Abbott Laboratories | $1,275.88 | 2021-2025 | Diamondback Coronary, Cardiomems, Mitraclip |
| Actelion Pharmaceuticals US, INC. | $999.31 | 2019-2025 | Uptravi, Opsumit |
| Pfizer INC. | $799.08 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $610.82 | 2020-2025 | |
| Boston Scientific Corporation | $586.35 | 2022-2025 | Ekosonic, Watchman Flx, Eluvia |
| Merck Sharp & Dohme LLC | $549.22 | 2022-2025 | Winrevair, Verquvo |
| Novo Nordisk INC | $443.24 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $438.91 | 2022-2025 | Onpattro |
| Abiomed | $419.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $415.36 | 2022-2025 | Farxiga, Wainua, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.89 | 2022-2025 | Jardiance |
| Cvrx, INC. | $205.70 | 2022-2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $186.30 | 2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Samson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.